Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Viktoryia Kazlouskaya

Dermatology Brooklyn, NY Medical Doctor

NPI 1013316330 CMS profile 648560

2797 Ocean Pkwy, Brooklyn, NY 11235

Open in the dashboard

General payments

$3,854

154 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Viktoryia Kazlouskaya of Brooklyn, NY is reported in the CMS Open Payments database as having received $3,854 across 154 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 59th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,474 63
2024 General $1,195 45
2023 General $667 30
2022 General $297 14
2021 General $161 1
2019 General $60 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Viktoryia Kazlouskaya
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Viktoryia Kazlouskaya were reported at $1,474. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Viktoryia Kazlouskaya Dermatology median Middle half National median
2019 $60 $454 $129–$1,240 $163
2020 $0 $235 $81–$756 $114
2021 $161 $377 $108–$1,108 $132
2022 $297 $514 $143–$1,391 $149
2023 $667 $607 $159–$1,674 $160
2024 $1,195 $751 $204–$1,903 $164
2025 $1,474 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Biotech, Inc. $589 14 payments
  2. AbbVie, Inc. $454 19 payments
  3. Novartis Pharmaceuticals Corporation $327 12 payments
  4. Arcutis Biotherapeutics, Inc. $308 16 payments
  5. E.R. Squibb & Sons, L.L.C. $298 14 payments
  6. Sun Pharmaceutical Industries Inc. $262 15 payments
  7. Lilly USA, LLC $235 10 payments
  8. Amgen Inc. $224 9 payments
  9. UCB, Inc. $213 9 payments
  10. Regeneron Healthcare Solutions, Inc. $202 9 payments
  11. Other $741 27 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,740 152 payments
  2. Education $114 2 payments
Products named General payments · program years 2019–2025
  1. TREMFYA $589 14 payments
  2. SOTYKTU $276 13 payments
  3. COSENTYX $268 9 payments
  4. SKYRIZI Immunology $252 9 payments
  5. Otezla $224 9 payments
  6. Bimzelx $213 9 payments
  7. Zoryve $210 10 payments
  8. OLUMIANT $208 9 payments
  9. ILUMYA $150 10 payments
  10. SKYRIZI Immunology $110 6 payments
  11. Other $1,135 53 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 40 drugs

Part D claims

2,753

Median for Dermatology: 534

Drug cost

$492,200

Median for Dermatology: $67,151

Branded share of claims

10.1%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Skyrizi Pen Risankizumab-Rzaa Brand 11 $224,407
Otezla Apremilast Brand 30 $143,257
Opzelura Ruxolitinib Phosphate Brand 18 $34,918
Zoryve Roflumilast Brand 33 $27,991
Ketoconazole Generic 612 $10,415
Clobetasol Propionate Generic 135 $7,272
Ammonium Lactate Generic 226 $4,077
Ivermectin Generic 13 $3,789
Clindamycin Phosphate Generic 75 $3,703
Halobetasol Propionate Generic 82 $3,638

The 10 drugs with the highest cost, of 40 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 72 billing codes

Paid by Medicare

$297,973

Of which drugs: $23,753

Medicare patients

1,048

Average age 78

Services billed

22,112

665 women, 383 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 71%
Diabetes 65%
Ischemic heart disease 50%
Depression 37%
Heart failure 29%
Osteoporosis 25%
Chronic kidney disease 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg J7345 Office 59 17,800 $23,646
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 36 135 $106

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $339
$339 — —
SKYRIZI
  • AbbVie, Inc. $130
$130 11 —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $85
  • GENZYME CORPORATION $30
$115 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $114
$114 — —
OLUMIANT
  • Lilly USA, LLC $98
$98 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

154 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record